Skip to main content
PMC home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
letter
. 2020 Aug 3;64(2):330–333. doi: 10.1007/s11427-020-1782-1

Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs

Bo Yu 1, Chenze Li 1, Peng Chen 1, Jia Li 2, Hualiang Jiang 2,3,✉, Dao-Wen Wang 1,✉
PMCID: PMC7406960  PMID: 32761451

The content is available as a PDF (824.1 KB).

Acknowledgements

We thank all medical staff and medical data managers for data extraction and help for analysis. We would like to thank Prof. Eric H. Xu at Shanghai Institute of Materia Medica, Chinese Academy of Sciences, for his useful suggestion and language improvement in writing this paper. This work was supported in part by the National Key R&D Program of Ministry of Science and Technology of China (2020YFC0844500), National Natural Science Foundation of China (31130031), Emergency Project Fund of Chinese Academy of Sciences (2020YJFK0105), and Chinese Academy of Engineering and Ma Yun Foundation (2020-CMKYGG-05).

Supporting Information

Patients and Methods (67.5KB, docx)

Footnotes

Compliance and ethics

The author(s) declare that they have no conflict of interest.

Contributor Information

Hualiang Jiang, Email: hljiang@simm.ac.cn.

Dao-Wen Wang, Email: dwwang@tjh.tjmu.edu.cn.

References

  1. Chen, C., Chen, C., Yan, J.T., Zhou, N., Zhao, J.P., and Wang, D.W. (2020). Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19 (in Chinese). Zhonghua Xin Xue Guan Bing Za Zhi 48, E008. [DOI] [PubMed]
  2. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720. doi: 10.1056/NEJMoa2002032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, Wang H, Wan J, Wang X, Lu Z. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19) JAMA Cardiol. 2020;5:811. doi: 10.1001/jamacardio.2020.1017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020;58:1021–1028. doi: 10.1515/cclm-2020-0369. [DOI] [PubMed] [Google Scholar]
  5. Huang, W., Li, C., Wang, Z., Wang, H., Zhou, N., Jiang, J., Ni, L., Zhang, X.A., and Wang, D.W. (2020). Decreased serum albumin level indicates poor prognosis of COVID-19 patients: hepatic injury analysis from 2,623 hospitalized cases. Sci China Life Sci 10.1007/s11427-020-1733-4. [DOI] [PMC free article] [PubMed]
  6. Ledford H. How does COVID-19 kill? Uncertainty is hampering doctors’ ability to choose treatments. Nature. 2020;580:311–312. doi: 10.1038/d41586-020-01056-7. [DOI] [PubMed] [Google Scholar]
  7. Liu C, Jiang ZC, Shao CX, Zhang HG, Yue HM, Chen ZH, Ma BY, Liu WY, Huang HH, Yang J, et al. Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study (in Chinese) Zhonghua Gan Zang Bing ZaZhi. 2020;28:148–152. doi: 10.3760/cma.j.issn.1007-3418.2020.02.003. [DOI] [PubMed] [Google Scholar]
  8. Liu W, Tao ZW, Wang L, Yuan ML, Liu K, Zhou L, Wei S, Deng Y, Liu J, Liu HG, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J. 2020;133:1032–1038. doi: 10.1097/CM9.0000000000000775. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ni L, Zhou L, Zhou M, Zhao J, Wang DW. Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19. Front Med. 2020;14:210–214. doi: 10.1007/s11684-020-0757-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Saqrane S, El Mhammedi MA. Review on the global epidemiological situation and the efficacy of chloroquine and hydroxychloroquine for the treatment of COVID-19. New Microb New Infect. 2020;35:100680. doi: 10.1016/j.nmni.2020.100680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Yu, B., Li, C., Chen, P., Zhou, N., Wang, L., Li, J., Jiang, H., and Wang, D. W. (2020). Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. Sci China Life Sci 10.1007/s11427-020-1732-2. [DOI] [PMC free article] [PubMed]

Articles from Science China. Life Sciences are provided here courtesy of Nature Publishing Group

RESOURCES